Sarepta (SRPT) announced screening and enrollment are underway in Cohort 8 of the ENDEAVOR study. The purpose of Cohort 8 is to assess prophylactic sirolimus treatment as part of an enhanced safety protocol during treatment with Elevidys in non-ambulant individuals with Duchenne muscular dystrophy.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Carvana, Warner Bros, Axon, Energy Fuels, Sarepta Insider Shakeup
- Sarepta price target raised to $31 from $26 at Mizuho
- Sarepta price target raised to $9 from $8 at Citi
- Controversial Prasad leaving FDA, NYT reports
- Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty